On Friday, RegenoCELL Therapeutics Inc. (OTCBB: RCL)?announced that their wholly owned subsidiary Regenocell, Ltd. is in the final stages of negotiations with several potential new distributors. The anticipation is that one or more will finalize by the end of this year and begin purchasing cell-processing services in the near term. This would have a beneficial impact on revenues generated by the cell processing operations.
It is expected that one or more of the new potential distributors will increase patient flow to Regenocell, Ltd., significantly increasing the use of existing capacity. The Company's stem cell therapy has successfully treated more than 500 patients, since 2005.
The typical patient is suffering from congestive heart failure with no treatment options and three to six months to live. More than five years later, patents initially treated are leading active and fulfilling lives. Less than a half liter of blood undergoes extraction from the patient and is sent to the Company's subsidiary cell processing facility in Israel. There, the patient's stem cells are extracted and grown from tens of thousands into many millions. Subsequently, the patient travels to a country that permits autologous therapy and has the stem cells transplanted in a hospital in a catheterization laboratory in a procedure similar to angioplasty.
Headquartered in Natick, Massachusetts, RegenoCELL Therapeutics is a stem cell therapy company using adult stem cells for autologous treatment of patients. Their plan is to obtain regulatory approval in the U.S. and the European Community to market their stem cell treatments. Via their wholly owned foreign subsidiaries, the Company is marketing their stem cell treatments for transplantation in countries where autologous therapy is permitted. The same RegenoCELL adult stem cell treatment can be used to treat peripheral artery disease.
Article written by QualityStocks �� Visit www.QualityStocks.net for more emerging growth companies to discover and evaluate.
For Quality Stocks full disclaimer, visit the company's Web site
No comments:
Post a Comment